{"analyses":[{"ciLowerLimit":"0.370","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.717","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"The priori threshold for statistical significance was 0.05.","paramType":"Hazard Ratio (HR)","paramValue":"0.515","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.11","upperLimit":"41.17","value":"25.99"},{"comment":"Median and the upper limit of the 95% confidence interval (CI) were not estimable due to an insufficient number of participants with events.","groupId":"OG001","lowerLimit":"41.20","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"191"}],"units":"Participants"}],"description":"rPFS: time interval from date of randomization to first date of radiographic progression as assessed by investigator or death due to any cause, whichever occurred first. rPFS was determined by: (1) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) per response evaluation criteria in solid tumors (RECIST) 1.1; (2) progression of bone lesions observed by bone scan per prostate cancer working group 3 (PCWG3) criteria: bone progression was confirmed by subsequent scan greater than or equal to (\\>=) 6 weeks later. Week 8 scan was baseline to which all subsequent scans were compared to determine progression. A confirmatory scan with \\>=2 new lesions indicated progression; A confirmatory scan not showing \\>=2 new lesions means no progression. If Week 8 scan shows \\<2 new bone lesions compared to baseline, first scan with \\>=2 new lesions compared to Week 8 scan indicated progression, when confirmed by a subsequent scan \\>=6 weeks later.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with deleterious germline or mCSPC and BRCA alterations were randomized to receive placebo matching to niraparib and AA fixed dose combination (FDC) tablets along with AA tablets (4\\*250 mg tablet) and prednisone 5 mg tablet orally, once daily from Day 1 of Cycle 1 up to 49 cycles. Each treatment cycle consisted of 28 days.","id":"OG000","title":"BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone"},{"description":"Participants with deleterious germline or somatic HRR gene-mutated mCSPC and BRCA alterations were randomized to receive niraparib and AA FDC tablets (2\\* \\[100 mg niraparib/500 mg AA tablet\\]) along with placebo matching to AA tablet and prednisone 5 mg tablet orally, once daily from Day 1 of Cycle 1 up to 49 cycles. Each treatment cycle consisted of 28 days.","id":"OG001","title":"BRCA Subgroup: Niraparib With Abiraterone Acetate Plus Prednisone"}],"paramType":"MEDIAN","populationDescription":"BRCA full analysis set (FAS) included all randomized participants with BRCA gene alteration classified according to their assigned treatment arm, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"From date of randomization (Day -3 to Day 1) up to approximately 49 months","title":"Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator","type":"PRIMARY","unitOfMeasure":"months"}